In collaboration with the University of Colorado, etectRx has made significant strides in advancing medication adherence monitoring through the QUANTI-TAF study (NCT04065347). Recently published in Clinical Infectious Diseases1 and the British Journal of Clinical Pharmacology2, the QUANTI-TAF study focused on antiretroviral therapy (ART) adherence among persons with HIV (PWH) receiving daily oral tenofovir alafenamide/emtricitabine (TAF/FTC)-based ART for at least…
